Health & Fit Immune therapy scores big win against lung cancer in study

18:40  16 april  2018
18:40  16 april  2018 Source:   Associated Press

New research finds more evidence of a link between severe gum disease and certain cancers

  New research finds more evidence of a link between severe gum disease and certain cancers New US research has provided more evidence to suggest that there is a link between advanced gum disease and an increased risk of cancer. Advanced gum disease, also called periodontitis, is caused by bacterial infection that damages the soft tissue and bone that support the teeth.  Although previous research has shown a link between periodontitis and an increased risk of cancer, the new study is the largest so far to look at the association using dental examinations to measure gum disease, rather than patient's self-reports.

Drugs are scoring big wins against common cancers , setting new standards for how to treat many tumors. Roche’s Alecensa stopped cancer growth for 15 months longer than Pfizer’s Xalkori did in a study of 303 people with advanced lung cancer and a mutation in a gene called ALK.

According to new studies released at a June 2017 American Society of Clinical Oncology conference, drugs are scoring big gains against some of the most common cancers , setting new standards of care for many prostate, breast and lung tumors.

This 2015 photo made available by Merck shows the drug Keytruda. Research released on Monday, April 16, 2018 suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common cancer types. Using one of these drugs _ Merck's Keytruda _ with usual chemotherapy extended survival for people newly diagnosed with the most common type of cancer that had spread beyond the lungs, one study found. (Michael Lund/Merck via AP) © The Associated Press This 2015 photo made available by Merck shows the drug Keytruda. Research released on Monday, April 16, 2018 suggests that many more lung cancer patients may benefit from treatments that boost the immune system, which have scored some of their biggest wins until now in less common cancer types. Using one of these drugs _ Merck's Keytruda _ with usual chemotherapy extended survival for people newly diagnosed with the most common type of cancer that had spread beyond the lungs, one study found. (Michael Lund/Merck via AP) CHICAGO — For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had much of its success until now in less common cancers.

New Details About Ami Brown's Cancer Fight

  New Details About Ami Brown's Cancer Fight He says she's not fully in the clear yet.Alaskan Bush People star Ami Brown revealed recently that she was declared cancer-free after a grueling battle with advanced lung cancer. Now, in an interview with People, her husband, family patriarch Billy, has opened up on the toll the cancer took on Ami-and how it felt to hear the great news from her doctor.

According to new studies released at a June 2017 American Society of Clinical Oncology conference, drugs are scoring big gains against some of the most common cancers , setting new standards of care for many prostate, breast and lung tumors.

CHICAGO (AP) — Drugs are scoring big wins against common cancers , setting new standards for how to treat many prostate, breast and lung tumors. There's even a "uni-drug" that may fight many forms of the disease.

In the study, Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year. The results are expected to quickly set a new standard of care for about 70,000 patients each year in the United States whose lung cancer has already spread by the time it's found.

Another study found that an immunotherapy combo — the Bristol-Myers Squibb drugs Opdivo and Yervoy — worked better than chemo for delaying the time until cancer worsened in advanced lung cancer patients whose tumors have many gene flaws, as nearly half do. But the benefit lasted less than two months on average and it's too soon to know if the combo improves overall survival, as Keytruda did.

A cancer 'vaccine' is completely eliminating tumors in mice

  A cancer 'vaccine' is completely eliminating tumors in mice A new cancer treatment experiment that used immune stimulators to target tumors in mice had remarkably encouraging results. After injecting a combination of two immune boosters directly into solid mouse tumors, the research team said the vaccination eliminated all traces of the specifically targeted cancer from the animal's entire body — including metastases that were previously untreated."When we use these two agents together, we see the elimination of tumors all over the body," senior author of the study, Dr. Ronald Levy told the Stanford Medicine News Center.

CHICAGO (AP) — Drugs are scoring big wins against common cancers than Pfizer’s Xalkori did in a study of 303 people with advanced lung cancer and a mutation in a gene called ALK. Last month, the FDA said Merck’s immune therapy drug Ketruda could be used for any pediatric or adult cancer

Drugs are scoring big wins against common cancers , setting new standards for how to treat many prostate, breast and lung tumors. There's even a "uni-drug" that may fight many forms of the disease.

All of these immune therapy treatments worked for only about half of patients, but that's far better than chemo has done in the past.

"We're not nearly where we need to be yet," said Dr. Roy Herbst, a Yale Cancer Center lung expert who had no role in the studies.

Results were discussed Monday at an American Association for Cancer Research conference in Chicago and published by the New England Journal of Medicine. The studies were sponsored by the drugmakers, and many study leaders and Herbst consult for the companies.

ABOUT THE DRUGS

Keytruda, Yervoy and Opdivo are called checkpoint inhibitors. They remove a cloak that some cancer cells have that hides them from the immune system. The drugs are given through IVs and cost about $12,500 a month.

Keytruda was approved last year as an initial treatment with chemo for the most common form of advanced lung cancer, but doctors have been leery to use it because that was based on a small study that did not show whether it prolongs life.

Is There a Connection Between Sleep and Lung Cancer?

  Is There a Connection Between Sleep and Lung Cancer? Sleep disorders might elevate risk for lung cancer or worsen prognosis in some patients. We all know that getting a good night's rest is helpful for overall health and wellness. But that basic rule of thumb may be even more true than we realize when it comes to cancer. Emerging science has begun to suggest that the critical function of sleep may have more to do with whether you develop cancer, particularly lung cancer, and how quickly it progresses.

CHICAGO >> Drugs are scoring big wins against common cancers , setting new standards for how to treat many prostate, breast and lung tumors. There’s even a “uni-drug” that may fight many forms of the disease.

CHICAGO — Drugs are scoring big wins against common cancers cancer growth for 15 months longer than Pfizer's Xalkori did in a study of 303 people with advanced lung cancer and a mutation in a Last month, the FDA said Merck's immune therapy drug Ketruda could be used for any pediatric

The new study, led by Dr. Leena Gandhi of NYU's Perlmutter Cancer Center, gives that proof. In it, 616 patients were given chemo and some also received Keytruda. Those not given Keytruda were allowed to switch to it if their cancer worsened.

After one year, 69 percent of people originally assigned to Keytruda were alive versus 49 percent of the others — a result that experts called remarkable considering that the second group's survival was improved because half of them wound up switching.

How much it ultimately will extend life isn't known — more than half in the Keytruda group are still alive; median survival was just over 11 months for the others.

The Keytruda combo also delayed the time until cancer worsened — an average of nine months versus five months for the chemo-only group.

That's a big difference for such an advanced cancer, said Dr. Alice Shaw, a Massachusetts General Hospital lung cancer expert and one of the conference leaders. "This is really a pivotal study ... a new standard of care," said Shaw, who has no ties to the drugmakers.

Rates of serious side effects were similar, but twice as many in the Keytruda group dropped out because of them. More than 4 percent of that group developed lung inflammation and three patients died of it.

Common STD may double ovarian cancer risk

  Common STD may double ovarian cancer risk This common STD can also cause infertility and often goes undetected. Can treating it quickly help protect women against later disease?The most common sexually transmitted disease can double a woman's risk of ovarian cancer, according to new research released Thursday.

Drugs are scoring big wins against common cancers , setting new standards for how to treat many prostate tumors, as well as breast and lung cancers , according to research presented at a Chicago medical conference.

CHICAGO — Drugs are scoring big wins against common cancers cancer growth for 15 months longer than Pfizer's Xalkori did in a study of 303 people with advanced lung cancer and a mutation in a Last month, the FDA said Merck's immune therapy drug Ketruda could be used for any pediatric

THE COMPETITION

Dr. Matthew Hellmann of Memorial Sloan Kettering Cancer Center in New York led a study testing the Opdivo-Yervoy combo versus chemo in a slightly different group of newly diagnosed advanced lung cancer patients.

The study design was changed after it was underway to look at results according to patients' tumor mutation burden — a measure of how flawed their cancer genes are, according to a profiling test by Foundation Medicine. Medicare recently agreed to cover the $3,000 test for advanced cancers.

Of 679 patients, 299 had a high number of gene flaws in their tumors. In that group, survival without worsening of disease was 43 percent after one year for those on the immunotherapy drugs versus 13 percent of those on chemo. The immunotherapy drugs did not help people with fewer tumor gene flaws.

"We have a tool that helps us determine who are the patients that are most likely to benefit from this combination," Hellmann said.

The median time until cancer worsened was about 7 months on the immunotherapy drugs versus 5.5 months for chemo. Serious side effects were a little more common in the chemo group.

Another rival, Genentech, recently announced that its checkpoint inhibitor, Tecentriq, improved survival in a study similar to the one testing Keytruda. Details are expected in a couple months.

Study: Cancer Vaccine Cures 97 Percent of Tumors in Mice, Human Trials to Begin Soon

  Study: Cancer Vaccine Cures 97 Percent of Tumors in Mice, Human Trials to Begin Soon <p>A new vaccine that cured 97 percent of cancerous tumors in mice has been approved for human trials.</p>A new vaccine that cured 97 percent of cancerous tumors in mice has been approved for human trials.

Drugs are scoring big wins against common cancers , setting new standards for how to treat many prostate, breast and lung tumors. There's even a "uni-drug" that may fight many forms of the disease.

Drugs are scoring big wins against common cancers , setting new standards for how to treat many prostate, breast and lung tumors. There's even a "uni-drug" that may fight many forms of the disease.

Marilynn Marchione can be followed on Twitter: @MMarchioneAP

Gallery: 7 signs of lung cancer you might be ignoring (courtesy Reader's Digest) Coughing up blood: 'Coughing up blood is never a good sign. Right then and there, go see your doctor,' says Raja Flores, MD, professor and chairman of thoracic surgery at Icahn School of Medicine at Mount Sinai in New York City. Although cancer may not necessarily be the cause of your bloody coughs, you should definitely get tested, he says. These are 15 cancer symptoms women are most likely to ignore. 7 signs of lung cancer you might be ignoring

The Associated Press Health & Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

Unintended weight loss is an important predictor of cancer finds new study .
A new UK meta-analysis has found that unintended weight loss is the second highest risk factor for certain cancers, including colorectal, lung, pancreatic and renal.&nbsp;Led by the Universities of Oxford and Exeter, the research is the first robust analysis to examine all available evidence to look at an association between weight loss and cancer.

—   Share news in the SOC. Networks

Topical videos:

This is interesting!